Biogen adds to neuromuscular franchise with $7.3B Reata deal, takes on EU risk

Though questions linger about whether the dataset for Reata’s therapy for Friedreich ataxia will be strong enough to capture EU approval, Biogen showed Friday that it is confident enough to assume that regulatory risk by acquiring Reata for $7.3 billion.

The deal comes as President and CEO Chris Viehbacher takes steps to reshape Biogen Inc. (NASDAQ:BIIB), and gives the big biotech a newly approved treatment that complements its neuromuscular rare disease holdings...